healio.com
/2 weeks ago
Zanidatamab regimens improve survival for gastroesophageal cancer
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...